Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 3
2019 1
2021 1
2022 3
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Implementing well-being in the management of psoriasis: An expert recommendation.
Sommer R, Mrowietz U, Gaarn Du Jardin K, Kasujee I, Martini E, Daudén E, Fabbrocini G, Zink A, Griffiths CEM, Augustin M. Sommer R, et al. Among authors: kasujee i. J Eur Acad Dermatol Venereol. 2024 Feb;38(2):302-310. doi: 10.1111/jdv.19567. Epub 2023 Oct 19. J Eur Acad Dermatol Venereol. 2024. PMID: 37822008 Review.
Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study).
Augustin M, Sommer R, Daudén E, Laws P, de Jong E, Fabbrocini G, Naldi L, Navarini A, Lambert J, Reguiai Z, Gerdes S, Massana E, Obis T, Kasujee I, Mrowietz U. Augustin M, et al. Among authors: kasujee i. BMJ Open. 2023 Feb 15;13(2):e060536. doi: 10.1136/bmjopen-2021-060536. BMJ Open. 2023. PMID: 36792337 Free PMC article.
Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice.
Costanzo A, Llamas-Velasco M, Fabbrocini G, Cuccia A, Rivera-Diaz R, Gaarn Du Jardin K, Kasujee I, Puig L, Carrascosa JM. Costanzo A, et al. Among authors: kasujee i. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2004-2015. doi: 10.1111/jdv.19229. Epub 2023 Jun 13. J Eur Acad Dermatol Venereol. 2023. PMID: 37246505
Application of the Statistical Method to Convert Published PASI 50/75/90/100 into Absolute PASI Response Rate in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab Based on Data from the Two Pivotal Phase 3 Studies reSURFACE 1 and reSURFACE 2.
Dykukha I, Schoenenberger A, Kasujee I, Mrowietz U, Vonthein R. Dykukha I, et al. Among authors: kasujee i. Dermatology. 2022;238(5):910-918. doi: 10.1159/000522009. Epub 2022 Feb 15. Dermatology. 2022. PMID: 35168231 Clinical Trial.
Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma.
Katsaounou P, Odemyr M, Spranger O, Hyland ME, Kroegel C, Conde LG, Gore R, Menzella F, Domingo Ribas C, Morais-Almeida M, Gasser M, Kasujee I. Katsaounou P, et al. Among authors: kasujee i. ERJ Open Res. 2018 Dec 21;4(4):00076-2018. doi: 10.1183/23120541.00076-2018. eCollection 2018 Oct. ERJ Open Res. 2018. PMID: 30588481 Free PMC article.
A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis.
Becher G, Conner S, Ingram JA, Stephen KE, McInnes AC, Heald AH, Riley PA, Davies M, Domenech A, Kasujee I. Becher G, et al. Among authors: kasujee i. Dermatol Ther (Heidelb). 2022 Oct;12(10):2343-2354. doi: 10.1007/s13555-022-00800-3. Epub 2022 Sep 9. Dermatol Ther (Heidelb). 2022. PMID: 36076145 Free PMC article.
14 results